US FDA's review of Prevnar-13 misses PDUFA date
This article was originally published in Scrip
Executive Summary
The US FDA's highly anticipated review of Pfizer's BLA for its 13-valent pneumococcal vaccine Prevnar-13 has surpassed its user fee date of December 30th.